TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: From pathomechanisms to therapeutic strategies
- PMID: 39069095
- DOI: 10.1016/j.arr.2024.102441
TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: From pathomechanisms to therapeutic strategies
Abstract
Proteostasis failure is a common pathological characteristic in neurodegenerative diseases. Revitalizing clearance systems could effectively mitigate these diseases. The transactivation response (TAR) DNA-binding protein 43 (TDP-43) plays a critical role as an RNA/DNA-binding protein in RNA metabolism and synaptic function. Accumulation of TDP-43 aggregates in the central nervous system is a hallmark of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Autophagy, a major and highly conserved degradation pathway, holds the potential for degrading aggregated TDP-43 and alleviating FTLD/ALS. This review explores the causes of TDP-43 aggregation, FTLD/ALS-related genes, key autophagy factors, and autophagy-based therapeutic strategies targeting TDP-43 proteinopathy. Understanding the underlying pathological mechanisms of TDP-43 proteinopathy can facilitate therapeutic interventions.
Keywords: Amyotrophic lateral sclerosis; Autophagy; Frontotemporal lobar degeneration; TDP-43.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare no conflict of interests.
Similar articles
-
Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.Hum Mol Genet. 2013 Oct 15;22(R1):R77-87. doi: 10.1093/hmg/ddt349. Epub 2013 Jul 29. Hum Mol Genet. 2013. PMID: 23900071 Free PMC article. Review.
-
Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.Int J Mol Sci. 2021 Apr 29;22(9):4705. doi: 10.3390/ijms22094705. Int J Mol Sci. 2021. PMID: 33946763 Free PMC article. Review.
-
Disease animal models of TDP-43 proteinopathy and their pre-clinical applications.Int J Mol Sci. 2013 Oct 9;14(10):20079-111. doi: 10.3390/ijms141020079. Int J Mol Sci. 2013. PMID: 24113586 Free PMC article. Review.
-
Annexin A11 aggregation in FTLD-TDP type C and related neurodegenerative disease proteinopathies.Acta Neuropathol. 2024 Jun 19;147(1):104. doi: 10.1007/s00401-024-02753-7. Acta Neuropathol. 2024. PMID: 38896345 Free PMC article.
-
Therapeutic effect of berberine on TDP-43-related pathogenesis in FTLD and ALS.J Biomed Sci. 2016 Oct 21;23(1):72. doi: 10.1186/s12929-016-0290-z. J Biomed Sci. 2016. PMID: 27769241 Free PMC article.
Cited by
-
Targeting Gene C9orf72 Pathogenesis for Amyotrophic Lateral Sclerosis.Int J Mol Sci. 2025 Apr 30;26(9):4276. doi: 10.3390/ijms26094276. Int J Mol Sci. 2025. PMID: 40362512 Free PMC article. Review.
-
N-Terminal Fragments of TDP-43-In Vitro Analysis and Implication in the Pathophysiology of Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.Genes (Basel). 2024 Sep 1;15(9):1157. doi: 10.3390/genes15091157. Genes (Basel). 2024. PMID: 39336748 Free PMC article.
-
Targeted degradation of α-synuclein by arginine-based PROTACs.J Biol Chem. 2025 Jul 2;301(8):110449. doi: 10.1016/j.jbc.2025.110449. Online ahead of print. J Biol Chem. 2025. PMID: 40615042 Free PMC article.
-
Decoding TDP-43: the molecular chameleon of neurodegenerative diseases.Acta Neuropathol Commun. 2024 Dec 31;12(1):205. doi: 10.1186/s40478-024-01914-9. Acta Neuropathol Commun. 2024. PMID: 39736783 Free PMC article. Review.
-
Exosomes in Regulating miRNAs for Biomarkers of Neurodegenerative Disorders.Mol Neurobiol. 2025 Jun;62(6):7576-7596. doi: 10.1007/s12035-025-04733-8. Epub 2025 Feb 7. Mol Neurobiol. 2025. PMID: 39918711 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous